Russell Investments Group Ltd. Buys 45,395 Shares of Insmed Incorporated (NASDAQ:INSM)

Russell Investments Group Ltd. grew its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 52.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 132,154 shares of the biopharmaceutical company's stock after buying an additional 45,395 shares during the period. Russell Investments Group Ltd. owned 0.07% of Insmed worth $9,124,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. National Bank of Canada FI increased its stake in Insmed by 9.7% during the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock worth $115,000 after purchasing an additional 147 shares in the last quarter. Abel Hall LLC increased its holdings in shares of Insmed by 4.7% during the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company's stock worth $230,000 after acquiring an additional 151 shares during the last quarter. Steward Partners Investment Advisory LLC increased its holdings in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares during the last quarter. M&T Bank Corp grew its stake in Insmed by 5.6% in the 4th quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock valued at $217,000 after buying an additional 166 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in Insmed by 5.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock worth $244,000 after purchasing an additional 183 shares during the last quarter.

Analyst Ratings Changes

Several analysts recently weighed in on INSM shares. Truist Financial raised their price objective on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Morgan Stanley lifted their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Finally, Stifel Nicolaus dropped their target price on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Insider Activity

In related news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the business's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the sale, the insider now directly owns 97,083 shares in the company, valued at $7,766,640. The trade was a 48.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO William Lewis sold 6,830 shares of the stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total value of $479,192.80. Following the sale, the chief executive officer now owns 233,924 shares of the company's stock, valued at approximately $16,412,107.84. This represents a 2.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 471,797 shares of company stock valued at $37,621,239 in the last three months. Corporate insiders own 3.00% of the company's stock.

Insmed Stock Up 1.1 %

Shares of NASDAQ:INSM traded up $0.76 during trading on Thursday, hitting $70.96. The company's stock had a trading volume of 321,457 shares, compared to its average volume of 2,264,573. The business has a 50 day moving average price of $75.60 and a two-hundred day moving average price of $73.60. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The company has a market capitalization of $12.90 billion, a PE ratio of -12.68 and a beta of 1.07.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, research analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.